Company
Blueprint Medicines
Blueprint Medicines has 11 drugs tracked on RxWires: 1 post-market, 1 in Phase 2/3, 1 in Phase 2, 1 in Phase 1/2, 7 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Avapritinib | Post-Market | Gastrointestinal Stromal Tumors |
| Elenestinib | Phase 2/3 | Indolent Systemic Mastocytosis |
| BLU-808 | Phase 2 | Chronic Inducible Urticaria |
| BLU-924 | Phase 1/2 | Advanced Solid Tumor |
| Fisogatinib (BLU-554) | Phase 1 | Hepatocellular Carcinoma (HCC) |
| BLU-451 | Phase 1 | Lung Neoplasm Malignant |
| BLU-263 | Phase 1 | Advanced Systemic Mastocytosis |
| BLU-701 | Phase 1 | Lung Neoplasm |
| BLU-945 | Phase 1 | Lung Neoplasms |
| BLU-782 | Phase 1 | Healthy Volunteers |
| BLU-222 | Phase 1 | Advanced Solid Tumors |
Latest
No recent events.
Follow Blueprint Medicines on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.